ArticleOncoimmunology2013
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Established and Emerging Therapies for High-Risk Neuroblastoma.Paediatric drugs · 2026Review
- Enhancing natural killer cell anti-tumour activity through macrophage manipulation.Frontiers in immunology · 2025Review
- Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma.Cancers · 2021Article
- Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.Exploration of targeted anti-tumor therapy · 2021Review
- Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic.International journal of molecular sciences · 2019Review
- Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy.Journal of pediatric hematology/oncology · 2019Article
- Anti-GD2 immunotherapy for neuroblastoma.Expert review of anticancer therapy · 2017Review
- Beta-glucan contamination of pharmaceutical products: How much should we accept?Cancer immunology, immunotherapy : CII · 2016Review
- In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Cancer research · 2016Article
- Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.Cancer medicine · 2015Article
- Trial Watch: Peptide-based anticancer vaccines.Oncoimmunology · 2015Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- GD2-targeted immunotherapy and radioimmunotherapy.Seminars in oncology · 2014Review
- Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.Oncoimmunology · 2014Review
- Immunotherapy in pediatric malignancies: current status and future perspectives.Future oncology (London, England) · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
β-glucans are complex, naturally-occurring polysaccharides that prime leukocyte dectin and complement receptor 3. Based on our preclinical findings, indicating that oral barley-derived (1 → 3),(1 → 4)-β-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.